Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin

Authors Pandian A, Arora A, Sperling L, Khan B

Published 10 October 2008 Volume 2008:4(5) Pages 1001—1009


Review by Single anonymous peer review

Peer reviewer comments 3

Anbu Pandian1, Anjali Arora2, Laurence S Sperling1, Bobby V Khan1

1Emory University School of Medicine and Grady Memorial Hospital Vascular Research Atlanta, Georgia USA; 2Sir Ganga Ram Hospital, New Delhi, India

Abstract: Dyslipidemia is a major risk factor in the initiation and progression of cardiovascular diseases such as atherosclerosis. Several pharmacological agents have been developed over the past 50 years which target various lipid components such as low density lipoprotein (LDL) cholesterol, triglyceride, and high density lipoprotein (HDL) cholesterol. Similar to other risk factors such as hypertension and diabetes mellitus, the management of dyslipidemia can be complicated and may require combination therapy for effective treatment. This review discusses the biochemical mechanisms of action and clinical uses for simvastatin (the most widely available and commercially prescribed statin) and niacin, and the combination of these agents in the management and treatment of dyslipidemia.

Keywords: dyslipidemia, HDL cholesterol, triglyceride, statin, niacin

Creative Commons License © 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.